[Skip to Navigation]
August 17, 2020

Normalization of Preexposure Prophylaxis for Adolescents: Empowerment, Not Vulnerability

Author Affiliations
  • 1Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles
  • 2Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles
JAMA Pediatr. 2020;174(12):1133-1134. doi:10.1001/jamapediatrics.2020.2545

The US Food and Drug Administration’s recent expansion in approval of emtricitabine/tenofovir (Truvada) for preexposure prophylaxis (PrEP) to youth who weigh more than 35 kg was a major gain for efforts to end the HIV epidemic among those aged 13 to 24 years, who accounted for 21% of all new HIV infections nationwide in 2017.1 Nonetheless, PrEP use remains low among individuals in this age group, including those who are sexual and gender minorities (and who are among those at the highest risk of HIV acquisition).2

Add or change institution